Annual Meeting of the NCI Cohort Consortium (Abstract Submission): Submission #12
Submission information
Submission Number: 12
Submission ID: 127577
Submission UUID: 7f5d9978-95b5-4d53-8853-a6249d46acac
Submission URI: /egrp/cohortconsortium/abstracts
Submission Update: /egrp/cohortconsortium/abstracts?token=LM0LzIfzM6Be3ODWgIBlaEdQyl7LXo2NH1ye4zlAskY
Created: Fri, 09/13/2024 - 14:24
Completed: Fri, 09/13/2024 - 16:02
Changed: Fri, 09/13/2024 - 16:02
Remote IP address: 10.208.28.69
Submitted by: Anonymous
Language: English
Is draft: No
Webform: Cohort 2024 (Abstracts Submission)
Lightning Talks Abstract
Benjamin
Cairns
Dr
Ph.D.
Our Future Health
Our Future Health: A New Prospective Cohort for Translational Research
Background: Our Future Health is a new UK-wide prospective cohort study supported by the UK Government, industry and charity sectors. Our objective is to recruit 5 million adult residents of the UK to facilitate aetiologic and translational health research, aiming to discover and test more effective approaches to prevention, earlier detection and treatment of diseases.
Methods: The sampling frame for Our Future Health is the total UK adult population. Through invitations and open enrolment, we aim to recruit a cohort that reflects the diversity of the UK population in terms of age, ethnicity, socioeconomic status and geography. Participants complete a questionnaire and attend an appointment for physical measurements and blood sampling, and are genotyped using a custom array with a genome-wide backbone for imputation and extensive coverage of disease- and phenotype-associated variants. Priority data linkages include primary and secondary care records, and cancer and death registrations, in each of the four UK nations.
Results: To date, 1.8 million participants have consented to join Our Future Health, of which 1.3 million have completed the broad baseline questionnaire and over 1 million have donated blood for genotyping and biobanking of plasma, buffy coat and DNA.
Discussion: Key translational aspects of the study include the forthcoming ability for study proposals to request access to baseline blood samples, and for investigator-led recontact studies to recruit participants based on demographics, phenotypes, genotypes or disease risk for risk-stratified research. Our Future Health (ourfuturehealth.org.uk) is already open for data access study proposals.
Methods: The sampling frame for Our Future Health is the total UK adult population. Through invitations and open enrolment, we aim to recruit a cohort that reflects the diversity of the UK population in terms of age, ethnicity, socioeconomic status and geography. Participants complete a questionnaire and attend an appointment for physical measurements and blood sampling, and are genotyped using a custom array with a genome-wide backbone for imputation and extensive coverage of disease- and phenotype-associated variants. Priority data linkages include primary and secondary care records, and cancer and death registrations, in each of the four UK nations.
Results: To date, 1.8 million participants have consented to join Our Future Health, of which 1.3 million have completed the broad baseline questionnaire and over 1 million have donated blood for genotyping and biobanking of plasma, buffy coat and DNA.
Discussion: Key translational aspects of the study include the forthcoming ability for study proposals to request access to baseline blood samples, and for investigator-led recontact studies to recruit participants based on demographics, phenotypes, genotypes or disease risk for risk-stratified research. Our Future Health (ourfuturehealth.org.uk) is already open for data access study proposals.